BARDOXOLONE

SynDRA canonical compound SYN0021688 — structure-anchored drug synonym record

Clinical phase	Phase 1
Primary target(s)	NFE2L2 \| NOS2 \| PPARG
Mechanism of action	nuclear factor erythroid derived, like (NRF2) activator

All known targets

Bardoxolona
CDDO
RTA-401
RTA401
RTA 401
2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid
UNII-7HT68L8941
7HT68L8941
(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid
C31H41NO4
2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid
RTA 402
CCDO;(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,7,8,8a,14a,14b-decahydropicene-4a-carboxylic acid
NSC711193
bardoxolone RTA 401
CDDO(Bardoxolone; RTA 401)
(+)-2-Cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid
Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-
(4AS,6AR,6BS,8AR,12AS,14AR,14BS)-11-CYANO-2,2,6A,6B,9,9,12A-HEPTAMETHYL-10,14-DIOXO-1,2,3,4,4A,5,6,6A,6B,7,8,8A,9,10,12A,14,14A,14B-OCTADECAHYDROPICENE-4A-CARBOXYLIC ACID
(4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,3,4,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-hexadecahydropicene-4a(2H)-carboxylic acid
BARDOXOLONE [MI]
BARDOXOLONE [INN]
Bardoxolone (USAN/INN)
Bardoxolone [USAN:INN]
BARDOXOLONE [USAN]
BARDOXOLONE [WHO-DD]
SCHEMBL954253
GTPL2717
CHEMBL1093059
CHEBI:177450
2-cyano-3,9-dien-28-oic acid
DTXSID001025273
BCP04662
EX-A1731
ZINC6019135
BDBM50096348
MFCD07772296
s6647
AKOS032960362